Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment

Stephanie V. Blank, Paul Christos, John P. Curtin, Noah Goldman, Carolyn D. Runowicz, Joseph A. Sparano, Leonard Liebes, Helen X. Chen, Franco M. Muggia

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background: The purpose of this study was to determine whether adding the anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to carboplatin/paclitaxel improved pathologic complete response (pCR) at reassessment surgery in epithelial ovarian, fallopian tube, or primary peritoneal cancers (OFPC). Methods: Patients with stage III-IV OFPC initiated treatment within 12 weeks of initial cytoreductive surgery or, after histologic confirmation of diagnosis, neoadjuvantly. Treatment included paclitaxel (175 mg/m2) and carboplatin (AUC 6) every 3 weeks for up to 6 cycles, plus oral erlotinib 150 mg daily. The primary objective was to determine whether the pCR rate at reassessment surgery was at least 60% after optimal cytoreduction at initial surgery (< 1 cm residual disease), or at least 40% after suboptimal cytoreduction (at least 1 cm residual disease) using a two-stage design (alpha = 0.10, beta = 0.10). Results: The study population included 56 patients with stage III-IV OFPC. EGFR gene amplification was present in 15% of the 20 tumors evaluated. Twenty-eight patients had protocol therapy after optimal cytoreduction (stratum I), 23 had protocol therapy either after suboptimal cytoreduction (stratum II), and 5 received neoadjuvant therapy prior to cytoreduction (stratum III). Pathologic CR was confirmed in 8 patients (29%; 95% confidence intervals 13%, 49%) in stratum I and 3 patients (11%, 95% C.I. 2%, 28%) in stratum II, which did not meet the prespecified efficacy endpoint in either stratum. Conclusions: Among unselected patients, erlotinib plus carboplatin-paclitaxel did not improve pCR rates compared with historical experience with carboplatin-paclitaxel alone in patients with stage III-IV OFPC.

Original languageEnglish (US)
Pages (from-to)451-456
Number of pages6
JournalGynecologic Oncology
Volume119
Issue number3
DOIs
StatePublished - Dec 2010

Fingerprint

Carboplatin
Paclitaxel
Ovarian Neoplasms
Therapeutics
erbB-1 Genes
Neoadjuvant Therapy
Fallopian Tubes
Gene Amplification
Erlotinib Hydrochloride
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Area Under Curve
Neoplasms
Confidence Intervals
Population

Keywords

  • Carboplatin
  • Erlotinib
  • Ovarian cancer
  • Paclitaxel
  • Reassessment surgery

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer : A phase II study based on surgical reassessment. / Blank, Stephanie V.; Christos, Paul; Curtin, John P.; Goldman, Noah; Runowicz, Carolyn D.; Sparano, Joseph A.; Liebes, Leonard; Chen, Helen X.; Muggia, Franco M.

In: Gynecologic Oncology, Vol. 119, No. 3, 12.2010, p. 451-456.

Research output: Contribution to journalArticle

Blank, Stephanie V. ; Christos, Paul ; Curtin, John P. ; Goldman, Noah ; Runowicz, Carolyn D. ; Sparano, Joseph A. ; Liebes, Leonard ; Chen, Helen X. ; Muggia, Franco M. / Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer : A phase II study based on surgical reassessment. In: Gynecologic Oncology. 2010 ; Vol. 119, No. 3. pp. 451-456.
@article{13b0279f38c04968b2ba63adfff1d35f,
title = "Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment",
abstract = "Background: The purpose of this study was to determine whether adding the anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to carboplatin/paclitaxel improved pathologic complete response (pCR) at reassessment surgery in epithelial ovarian, fallopian tube, or primary peritoneal cancers (OFPC). Methods: Patients with stage III-IV OFPC initiated treatment within 12 weeks of initial cytoreductive surgery or, after histologic confirmation of diagnosis, neoadjuvantly. Treatment included paclitaxel (175 mg/m2) and carboplatin (AUC 6) every 3 weeks for up to 6 cycles, plus oral erlotinib 150 mg daily. The primary objective was to determine whether the pCR rate at reassessment surgery was at least 60{\%} after optimal cytoreduction at initial surgery (< 1 cm residual disease), or at least 40{\%} after suboptimal cytoreduction (at least 1 cm residual disease) using a two-stage design (alpha = 0.10, beta = 0.10). Results: The study population included 56 patients with stage III-IV OFPC. EGFR gene amplification was present in 15{\%} of the 20 tumors evaluated. Twenty-eight patients had protocol therapy after optimal cytoreduction (stratum I), 23 had protocol therapy either after suboptimal cytoreduction (stratum II), and 5 received neoadjuvant therapy prior to cytoreduction (stratum III). Pathologic CR was confirmed in 8 patients (29{\%}; 95{\%} confidence intervals 13{\%}, 49{\%}) in stratum I and 3 patients (11{\%}, 95{\%} C.I. 2{\%}, 28{\%}) in stratum II, which did not meet the prespecified efficacy endpoint in either stratum. Conclusions: Among unselected patients, erlotinib plus carboplatin-paclitaxel did not improve pCR rates compared with historical experience with carboplatin-paclitaxel alone in patients with stage III-IV OFPC.",
keywords = "Carboplatin, Erlotinib, Ovarian cancer, Paclitaxel, Reassessment surgery",
author = "Blank, {Stephanie V.} and Paul Christos and Curtin, {John P.} and Noah Goldman and Runowicz, {Carolyn D.} and Sparano, {Joseph A.} and Leonard Liebes and Chen, {Helen X.} and Muggia, {Franco M.}",
year = "2010",
month = "12",
doi = "10.1016/j.ygyno.2010.08.008",
language = "English (US)",
volume = "119",
pages = "451--456",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer

T2 - A phase II study based on surgical reassessment

AU - Blank, Stephanie V.

AU - Christos, Paul

AU - Curtin, John P.

AU - Goldman, Noah

AU - Runowicz, Carolyn D.

AU - Sparano, Joseph A.

AU - Liebes, Leonard

AU - Chen, Helen X.

AU - Muggia, Franco M.

PY - 2010/12

Y1 - 2010/12

N2 - Background: The purpose of this study was to determine whether adding the anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to carboplatin/paclitaxel improved pathologic complete response (pCR) at reassessment surgery in epithelial ovarian, fallopian tube, or primary peritoneal cancers (OFPC). Methods: Patients with stage III-IV OFPC initiated treatment within 12 weeks of initial cytoreductive surgery or, after histologic confirmation of diagnosis, neoadjuvantly. Treatment included paclitaxel (175 mg/m2) and carboplatin (AUC 6) every 3 weeks for up to 6 cycles, plus oral erlotinib 150 mg daily. The primary objective was to determine whether the pCR rate at reassessment surgery was at least 60% after optimal cytoreduction at initial surgery (< 1 cm residual disease), or at least 40% after suboptimal cytoreduction (at least 1 cm residual disease) using a two-stage design (alpha = 0.10, beta = 0.10). Results: The study population included 56 patients with stage III-IV OFPC. EGFR gene amplification was present in 15% of the 20 tumors evaluated. Twenty-eight patients had protocol therapy after optimal cytoreduction (stratum I), 23 had protocol therapy either after suboptimal cytoreduction (stratum II), and 5 received neoadjuvant therapy prior to cytoreduction (stratum III). Pathologic CR was confirmed in 8 patients (29%; 95% confidence intervals 13%, 49%) in stratum I and 3 patients (11%, 95% C.I. 2%, 28%) in stratum II, which did not meet the prespecified efficacy endpoint in either stratum. Conclusions: Among unselected patients, erlotinib plus carboplatin-paclitaxel did not improve pCR rates compared with historical experience with carboplatin-paclitaxel alone in patients with stage III-IV OFPC.

AB - Background: The purpose of this study was to determine whether adding the anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to carboplatin/paclitaxel improved pathologic complete response (pCR) at reassessment surgery in epithelial ovarian, fallopian tube, or primary peritoneal cancers (OFPC). Methods: Patients with stage III-IV OFPC initiated treatment within 12 weeks of initial cytoreductive surgery or, after histologic confirmation of diagnosis, neoadjuvantly. Treatment included paclitaxel (175 mg/m2) and carboplatin (AUC 6) every 3 weeks for up to 6 cycles, plus oral erlotinib 150 mg daily. The primary objective was to determine whether the pCR rate at reassessment surgery was at least 60% after optimal cytoreduction at initial surgery (< 1 cm residual disease), or at least 40% after suboptimal cytoreduction (at least 1 cm residual disease) using a two-stage design (alpha = 0.10, beta = 0.10). Results: The study population included 56 patients with stage III-IV OFPC. EGFR gene amplification was present in 15% of the 20 tumors evaluated. Twenty-eight patients had protocol therapy after optimal cytoreduction (stratum I), 23 had protocol therapy either after suboptimal cytoreduction (stratum II), and 5 received neoadjuvant therapy prior to cytoreduction (stratum III). Pathologic CR was confirmed in 8 patients (29%; 95% confidence intervals 13%, 49%) in stratum I and 3 patients (11%, 95% C.I. 2%, 28%) in stratum II, which did not meet the prespecified efficacy endpoint in either stratum. Conclusions: Among unselected patients, erlotinib plus carboplatin-paclitaxel did not improve pCR rates compared with historical experience with carboplatin-paclitaxel alone in patients with stage III-IV OFPC.

KW - Carboplatin

KW - Erlotinib

KW - Ovarian cancer

KW - Paclitaxel

KW - Reassessment surgery

UR - http://www.scopus.com/inward/record.url?scp=78149360639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149360639&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2010.08.008

DO - 10.1016/j.ygyno.2010.08.008

M3 - Article

C2 - 20837357

AN - SCOPUS:78149360639

VL - 119

SP - 451

EP - 456

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -